Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. The company offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. It also provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic, cardiology, dermatology, diabetes, fever, gastroenterology, hematology, helminthics, hepatoprotective, immunosuppressant, infectious disease, malarial, neurology, nutraceuticals, ophthalmology, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology, as well as products in various dosage forms comprising oral solids, powders for suspension, and liquid and dry injections. The company exports its products to approximately 100 countries worldwide. It has an agreement with Medicines for Malaria Venture to develop a novel antimalarial co-formulation named Atoguanil. The company was incorporated in 1949 and is based in Mumbai, India. The ISIN of this stock is INE571A01020.